Trial Profile
Randomised phase II trial of cabozantinib as second-line therapy in patients with non-small cell lung cancer.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 May 2012
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 May 2012 New trial record